Phare Bio
Phare Bio is a social venture using generative AI and deep learning to discover novel antibiotics against urgent drug-resistant threats. Its AIBiotics platform screens 1000x more molecules, 5x faster, at 100x greater success rate than traditional methods, targeting pathogens like Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae. The company addresses the preclinical "valley of death" with donor funding before partnering commercially for clinical development.
- Drug Discovery & Therapeutics
- Biotechnology
- Artificial Intelligence
- Healthcare Technology
Funding
Founders
Founder details are not available yet.
Product
Problem
Antibiotic resistance is a growing global health crisis, with resistant infections expected to reach 10 million annual deaths by 2050 and surpass cancer as a leading cause of death. Pharmaceutical and biotechnology companies have largely abandoned antibiotic development for more lucrative markets, leaving a critical gap in the pipeline for new treatments against deadly bacteria.
Solution
Phare Bio is a social venture building AIBiotics, a generative AI antibiotics discovery engine that designs and develops novel antibiotics against urgent threats such as Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae. The platform screens 1000x as many molecules, 5x faster, at 100x greater success rate compared to traditional methods, using the negligible cost of computing to predict and design new drug candidates. Phare addresses the "valley of death" in preclinical development with donor funding, then partners commercially for costly clinical development, creating a sustainable path to bring therapies to patients in greatest need.
Target Audience
Primary stakeholders are patients with drug-resistant infections, healthcare systems facing antimicrobial resistance, and public health organizations seeking new antibiotic therapies. The company also serves philanthropic funders and commercial pharmaceutical partners interested in derisked antibiotic candidates.
Features
- Generative AI platform for novel antibiotic discovery, developed in partnership with the Collins Lab at MIT
- Screens 1000x more molecules, 5x faster, with 100x greater success rate than conventional approaches
- AI-designed candidates undergo hit-to-lead optimization including drug metabolism, toxicology, pharmacokinetics, and efficacy assays
- Preclinical development includes drug delivery testing and extensive in vivo efficacy profiling
- Focus on WHO-priority pathogens including Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae